MARYLAND: The coronavirus vaccine developed by the US company Novavax has demonstrated 89.3 per cent efficacy during the phase 3 trials conducted in the United Kingdom, the company said in a statement.
“Novavax, Inc, a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3 per cent, in its Phase 3 clinical trial conducted in the United Kingdom (UK),” the company said in a statement on late Thursday.
In July, Novavax received USD 1.6 billion from the US government to develop the vaccine against the coronavirus. The European Union, the Philippines, Australia, and New Zealand have already expressed their wish to purchase this vaccine.
The World Health Organization declared the COVID-19 outbreak a pandemic on March 11. To date, more than 101.2 million people have been infected with the coronavirus worldwide, with over 2.18 million fatalities, according to Johns Hopkins University. (ANI/Sputnik)